General Information of Drug Off-Target (DOT) (ID: OTWARAMR)

DOT Name Microtubule nucleation factor SSNA1 (SSNA1)
Synonyms Nuclear autoantigen of 14 kDa; Sjoegren syndrome nuclear autoantigen 1
Gene Name SSNA1
Related Disease
Peeling skin syndrome 1 ( )
Potocki-Shaffer syndrome ( )
Systemic sclerosis ( )
UniProt ID
SSNA1_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MTQQGAALQNYNNELVKCIEELCQKREELCRQIQEEEDEKQRLQNEVRQLTEKLARVNEN
LARKIASRNEFDRTIAETEAAYLKILESSQTLLSVLKREAGNLTKATAPDQKSSGGRDS
Function
Microtubule-binding protein which stabilizes dynamic microtubules by slowing growth and shrinkage at both plus and minus ends and serves as a sensor of microtubule damage, protecting microtubules from the microtubule-severing enzyme SPAST. Induces microtubule branching which is mediated by the formation of long SSNA1 fibrils which guide microtubule protofilaments to split apart from the mother microtubule and form daughter microtubules. Plays a role in axon outgrowth and branching. Required for cell division.
Tissue Specificity Widely expressed.
Reactome Pathway
Loss of Nlp from mitotic centrosomes (R-HSA-380259 )
Recruitment of mitotic centrosome proteins and complexes (R-HSA-380270 )
Loss of proteins required for interphase microtubule organization from the centrosome (R-HSA-380284 )
Recruitment of NuMA to mitotic centrosomes (R-HSA-380320 )
Anchoring of the basal body to the plasma membrane (R-HSA-5620912 )
AURKA Activation by TPX2 (R-HSA-8854518 )
Regulation of PLK1 Activity at G2/M Transition (R-HSA-2565942 )

Molecular Interaction Atlas (MIA) of This DOT

3 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Peeling skin syndrome 1 DIS35574 Definitive Biomarker [1]
Potocki-Shaffer syndrome DISKGU59 Definitive Biomarker [1]
Systemic sclerosis DISF44L6 Definitive Biomarker [1]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate increases the methylation of Microtubule nucleation factor SSNA1 (SSNA1). [2]
------------------------------------------------------------------------------------
4 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Ivermectin DMDBX5F Approved Ivermectin decreases the expression of Microtubule nucleation factor SSNA1 (SSNA1). [3]
Marinol DM70IK5 Approved Marinol decreases the expression of Microtubule nucleation factor SSNA1 (SSNA1). [4]
Selenium DM25CGV Approved Selenium increases the expression of Microtubule nucleation factor SSNA1 (SSNA1). [5]
Milchsaure DM462BT Investigative Milchsaure decreases the expression of Microtubule nucleation factor SSNA1 (SSNA1). [6]
------------------------------------------------------------------------------------

References

1 The orthologue of Sjgren's syndrome nuclear autoantigen 1 (SSNA1) in Trypanosoma brucei is an immunogenic self-assembling molecule.PLoS One. 2012;7(2):e31842. doi: 10.1371/journal.pone.0031842. Epub 2012 Feb 20.
2 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
3 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
4 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
5 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
6 Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.